Cellectis Cash Flow Conversion Efficiency

Latest as of June 2026: -0.348x

Cellectis cash flow conversion efficiency. Based on the latest financial reports, Cellectis (ALCLS) has a cash flow conversion efficiency ratio of -0.348x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-14.28 Million ≈ $-16.70 Million USD) by net assets (€41.07 Million ≈ $48.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Cellectis (2005–2025)

Cash flow conversion efficiency of Cellectis from 2005 to 2025. This chart illustrates how Cellectis's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ALCLS share price today for real-time trading data and today's change.

Cellectis Cash Flow Conversion Ratio Explained

Cellectis cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Cellectis Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cellectis ranked by their cash flow conversion efficiency. Also see Cellectis market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Right Way Industrial Co Ltd TW:1506	0.008x
Sao Ta Foods JSC VN:FMC	0.089x
Chateau International Development Co Ltd TW:2722	0.010x
Rithm Property Trust Inc. NYSE:RPT	-0.002x
Gigante Salmon AS OL:GIGA	0.013x
Téléverbier SA PA:TVRB	0.232x
Dwarikesh Sugar Industries Limited NSE:DWARKESH	0.674x
Lionsgate Studios Holding Corp. (to be renamed Lionsgate Studios Corp.) NASDAQ:LION	0.172x

Annual Cash Flow Conversion Efficiency for Cellectis (2005–2025)

The table below shows the annual cash flow conversion efficiency of Cellectis from 2005 to 2025. Review cash generation quality of Cellectis to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€75.87 Million ≈ $88.70 Million	€-41.64 Million ≈ $-48.69 Million	-0.549x	-412.85%
2024-12-31	€131.03 Million ≈ $153.19 Million	€22.99 Million ≈ $26.88 Million	0.175x	+160.05%
2023-12-31	€84.69 Million ≈ $99.02 Million	€-24.75 Million ≈ $-28.93 Million	-0.292x	+57.92%
2022-12-31	€125.94 Million ≈ $147.24 Million	€-87.44 Million ≈ $-102.23 Million	-0.694x	-57.03%
2021-12-31	€236.47 Million ≈ $276.46 Million	€-104.56 Million ≈ $-122.24 Million	-0.442x	-70.15%
2020-12-31	€308.85 Million ≈ $361.07 Million	€-80.26 Million ≈ $-93.83 Million	-0.260x	-33.61%
2019-12-31	€355.47 Million ≈ $415.58 Million	€-69.14 Million ≈ $-80.83 Million	-0.195x	-28.54%
2018-12-31	€450.27 Million ≈ $526.41 Million	€-68.14 Million ≈ $-79.66 Million	-0.151x	+17.32%
2017-12-31	€285.90 Million ≈ $334.25 Million	€-52.33 Million ≈ $-61.18 Million	-0.183x	-61.34%
2016-12-31	€274.05 Million ≈ $320.39 Million	€-31.09 Million ≈ $-36.34 Million	-0.113x	-1024.12%
2015-12-31	€288.22 Million ≈ $336.95 Million	€3.54 Million ≈ $4.14 Million	0.012x	-98.25%
2014-12-31	€72.39 Million ≈ $84.63 Million	€50.74 Million ≈ $59.32 Million	0.701x	+118.19%
2013-12-31	€6.65 Million ≈ $7.77 Million	€-25.63 Million ≈ $-29.96 Million	-3.854x	-1105.67%
2012-12-31	€81.69 Million ≈ $95.50 Million	€-26.11 Million ≈ $-30.53 Million	-0.320x	+10.29%
2011-12-31	€37.02 Million ≈ $43.28 Million	€-13.19 Million ≈ $-15.42 Million	-0.356x	+15.35%
2010-12-31	€50.13 Million ≈ $58.60 Million	€-21.10 Million ≈ $-24.67 Million	-0.421x	-337.25%
2009-12-31	€73.22 Million ≈ $85.60 Million	€-7.05 Million ≈ $-8.24 Million	-0.096x	-350.06%
2008-12-31	€46.21 Million ≈ $54.03 Million	€1.78 Million ≈ $2.08 Million	0.038x	+129.82%
2007-12-31	€43.54 Million ≈ $50.91 Million	€-5.62 Million ≈ $-6.57 Million	-0.129x	-400.76%
2005-12-31	€9.11 Million ≈ $10.65 Million	€391.00K ≈ $457.12K	0.043x	--

About Cellectis

PA:ALCLS France Biotechnology

Market Cap

$85.44 Million

€73.08 Million EUR

Market Cap Rank

#19558 Global

#294 in France

Share Price

€1.01

Change (1 day)

-4.10%

52-Week Range

€0.94 - €4.57

All Time High

€40.90